Survodutide Phase 2 trial (NCT04153929)
A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus.
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 413
- actual
- Start
- 30 Apr 2020 (actual)
- Primary completion
- 8 Oct 2021 (actual)
- Sponsor
- Boehringer Ingelheim
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| BI 456906 0.3 mg | Experimental | Drug: BI 456906 | Not stated |
| BI 456906 0.9 mg | Experimental | Drug: BI 456906 | Not stated |
| BI 456906 1.8 mg | Experimental | Drug: BI 456906 | Not stated |
| BI 456906 2.7 mg | Experimental | Drug: BI 456906 | Not stated |
| BI 456906 1.2 twice weekly (2.4) mg | Experimental | Drug: BI 456906 | Not stated |
| BI 456906 1.8 twice weekly (3.6) mg | Experimental | Drug: BI 456906 | Not stated |
| Semaglutide | Active comparator | Drug: Semaglutide | Not stated |
| Placebo | Placebo comparator | Drug: Placebo | Not stated |
Primary endpoint
| Measure | Time frame |
|---|---|
| Absolute Change in HbA1c From Baseline to 16 Weeks | At baseline and at Week 17 (16 weeks after treatment start). |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Key Secondary Endpoint: The Relative Change in Body Weight From Baseline to 16 Weeks | At baseline and at Week 17 (16 weeks after treatment start ). |
| The Absolute Change in Body Weight From Baseline to 16 Weeks | At baseline and at Week 17 (16 weeks after treatment start). |
| The Absolute Change in Waist Circumference From Baseline to 16 Weeks | At baseline and at Week 17 (16 weeks after treatment start). |
| Percentage of Patients With 5 % or Greater Body Weight Loss From Baseline to 16 Weeks | At baseline and at Week 17 (16 weeks after treatment start). |
| Percentage of Patients With 10% or Greater Body Weight Loss From Baseline to 16 Weeks | At baseline and at Week 17 (16 weeks after treatment start). |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04153929.
Survodutide in type 2 diabetes, dose-response against semaglutide
Participants with type 2 diabetes on metformin were randomised across six survodutide dose groups, placebo, or open-label semaglutide up to 1.0 mg weekly.[2]
The HbA1c reduction was similar for low-dose survodutide (-1.46%) and semaglutide (-1.47%).[2]
Bodyweight fell by up to 8.7% on survodutide, and doses of 1.8 mg weekly or more outperformed semaglutide (-5.3%).[2]
Adverse events, mainly gastrointestinal, were reported for 77.8% of survodutide recipients, 52.5% on placebo and 52.0% on semaglutide.[2]
Sources
- 1A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus.ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.Diabetologia · 2024PMID 38095657Accessed 2 Oct 2026
Found an error? Report a correction.